Neoplasms

Respiratory Tract (Lung and Bronchial) Diseases

All Conditions

Symptoms and General Pathology

Blood and Lymph Conditions

Immune System Diseases

Digestive System Diseases

Skin and Connective Tissue Diseases

Rare Diseases

Lung Neoplasms

Syndrome

Leukemia

Mastocytosis

Gastrointestinal Stromal Tumors

Hypersensitivity

Leukemia, Myeloid

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

Leukemia, Myelomonocytic, Chronic

Leukemia, Myelomonocytic, Juvenile

Mastocytosis, Systemic

Hypereosinophilic Syndrome

Dermatofibrosarcoma

Neoplasms by Histologic Type

Hematologic Diseases

Myeloproliferative Disorders

Myelodysplastic-Myeloproliferative Diseases

Bone Marrow Diseases

Chronic Disease

Disease Attributes

Neoplasms, Connective Tissue

Neoplasms, Connective and Soft Tissue

Mast Cell Activation Disorders

Eosinophilia

Leukocyte Disorders

Fibrosarcoma

Neoplasms, Fibrous Tissue

Sarcoma

Myeloid Leukemia

Chronic Graft Versus Host Disease

Chronic Myeloid Leukemia

Chronic Myelomonocytic Leukemia

Juvenile Myelomonocytic Leukemia

Systemic Mastocytosis

Dermatofibrosarcoma Protuberans

Chronic Myeloproliferative Disorders

Myelodysplastic/myeloproliferative Disease

Soft Tissue Sarcoma

Antineoplastic Agents

All Drugs and Chemicals

Amino Acids

Imatinib Mesylate

Tyrosine Kinase Inhibitors

Protein Kinase Inhibitors

Enzyme Inhibitors

Tyrosine

imatinib mesylate

Novartis Pharmaceuticals

This trial is for various types of malignancies which may depend on certain enzymes (tyrosine kinases) for growth. The objective of this study is to assess to what extent imatinib mesylate blocks these enzymes and to assess the effect on the malignancy.

Condition

Diverse malignancies either associated with or thought to be associated with activated tyrosine kinase enzymes including hypereosinophilic syndrome systemic mastocytosis chronic myelomonocytic leukaemia, dermatofibrosarcoma protuberans and other diseases.

Not included:

Patients with chronic myeloid leukemia, some other types of leukemias (abl-mutated) some types of gastrointestinal stromal tumours (c-KIT-positive), some systemic mastocytosis (if c-KIT D816V mutation), brain, prostate, breast or lung cancers.

Imatinib Mesylate in Patients With Various Types of Malignancies Involving Activated Tyrosine Kinase Enzymes

Urinary Tract, Sexual Organs, and Pregnancy Conditions

Infections

Prostatic Neoplasms

Communicable Diseases

Genital Neoplasms, Male

Urogenital Neoplasms

Genital Diseases

Genital Diseases, Male

Urogenital Diseases

Prostatic Diseases

Male Urogenital Diseases

Anti-Infective Agents

Anti-Bacterial Agents

Ciprofloxacin

Antibiotics, Antitubercular

Cytochrome P-450 Enzyme Inhibitors

Ciprofloxacine

Irani Jacques, professor

The purpose of this study is to determine whether long antibiotic prophylactic is more effective than a short traitement in infective complications for prostate biopsy

Prophylactic antibiotic is used to minimize the infective complications risk following transrectal biopsy of the prostate.

The majority of works points to the need of antibiotic prophylaxis previously to transrectal prostate biopsy. However, there is a lot of controversy and diversity of therapeutic schemes in the literature concerning the ideal drug to be used and the time employed for infectious prophylaxis.

The objective of this randomised study was to assess 2 different schemes of antimicrobial prophylaxis, aiming to determine the difference in infective complications with a single dose of ciprofloxacin 2 hours before the procedure vs. ciprofloxacin for 3 days

Short or Long Schemes of Antibiotic Prophylaxis for Prostate Biopsy

Comparison Between Short and Long Schemes of Antibiotic Prophylaxis for Transrectal Prostate Biopsy. A Multicentre Prospective Randomised Study

Poitiers University Hospital

Esophageal Neoplasms

Head and Neck Neoplasms

Gastrointestinal Neoplasms

Digestive System Neoplasms

Gastrointestinal Diseases

Esophageal Diseases

Esophageal Cancer

Panobinostat

Histone Deacetylase Inhibitors

panobinostat

The purpose of this study is to assess the feasibility of combined administration of different LBH589 dosages with radiotherapy in order to establish the dosage to be evaluated in future studies.

A Phase I Study of LBH589 (Panobinostat) in Combination With External Beam Radiotherapy for the Treatment of Prostate Cancer, Esophageal Cancer and Head and Neck Cancer

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
Imatinib Mesylate in Patients With Various Types of Malignancies Involving Activated Tyrosine Kinase Enzymes	NCT00171912	Hypereosinophil... Systemic Mastoc... Chronic Myelomo... Dermatofibrosar...	imatinib mesyla...	16 Years - 80 Years	Novartis
Short or Long Schemes of Antibiotic Prophylaxis for Prostate Biopsy	NCT00294749	Men Who Must Un...	Ciprofloxacine	18 Years -	Poitiers University Hospital
A Phase I Study of LBH589 (Panobinostat) in Combination With External Beam Radiotherapy for the Treatment of Prostate Cancer, Esophageal Cancer and Head and Neck Cancer	NCT00670553	Prostate Cancer Head & Neck Can... Esophageal Canc...	panobinostat	18 Years -	Novartis
Short or Long Schemes of Antibiotic Prophylaxis for Prostate Biopsy	NCT00294749	Men Who Must Un...	Ciprofloxacine	18 Years -	Poitiers University Hospital

Spots Global Cancer Trial Database for prostate,

Every month we try and update this database with for prostate, cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

Spots Global Cancer Trial Database for prostate,

Every month we try and update this database with for prostate, cancer trials from around the world to help patients and their families find trials that might be right for them. We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

Every month we try and update this database with for prostate, cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.